The best-known story in European pharmaceuticals right now is Danish: Novo Nordisk, the Copenhagen-listed maker of Ozempic, Wegovy and the oral diabetes drug Rybelsus, has become the most valuable company in Europe on the back of the global appetite-suppressant boom. Less well known is that part of the deep manufacturing science behind those medicines runs through a family-controlled factory on the northern edge of Lisbon. That company is Hovione — and it is one of the most quietly consequential threads in the Portugal–Nordic corridor.
A Portuguese original. Hovione was founded in 1959 by the Hungarian-born chemist Ivan Villax, his wife Diane and two fellow refugees; the name stitches together the first letters of the three founders’ surnames. Nearly seven decades later it is still privately held, still headquartered in Loures, just outside Lisbon, and has grown into a genuinely global contract development and manufacturing organisation (CDMO) — the specialist firms that pharmaceutical companies hire to develop and make the active ingredients inside their drugs. Hovione runs FDA-inspected plants in Portugal, Ireland, the United States and China, employs on the order of a thousand people, and was the first chemical-pharmaceutical company in the world to become a certified B Corporation. It is also the largest private employer of PhDs in Portugal, with dozens of doctorates concentrated at its Loures research campus.
Where the Nordic link comes in. Hovione’s expertise sits precisely where the obesity-drug wave is hardest: turning fragile, complex molecules into stable, manufacturable medicines. The company has been identified in the supply chain of Rybelsus, Novo Nordisk’s oral form of semaglutide — the same active ingredient as in the injectable Ozempic and Wegovy, but engineered into a tablet a patient can swallow. Novo Nordisk manufactures its own semaglutide at scale in Kalundborg, Denmark; the surrounding ecosystem of particle engineering, formulation and specialty manufacturing is exactly the territory where a CDMO like Hovione earns its place. It is a business-to-business relationship of the least glamorous and most durable kind: a Portuguese specialist embedded in the industrial machinery of a Danish champion.
Why the technology matters. Making a peptide like semaglutide work as an oral pill is one of the harder problems in modern pharmaceutics — peptides are large, delicate and easily destroyed in the gut. The techniques that make it possible, chief among them spray drying and particle engineering, are Hovione’s core competencies; the company has spent decades and hundreds of millions of euros building spray-drying and continuous-manufacturing capacity, much of it in Portugal. As the industry races to convert injectable blockbusters into oral versions — Novo Nordisk itself has been pushing an oral Wegovy toward market — that particular expertise becomes strategically scarce, and Portugal happens to host one of the world’s deepest benches of it.
The scale of the demand. The GLP-1 class that includes semaglutide has moved from a diabetes niche to a mass-market phenomenon, with chronic shortages and a multi-year race to expand capacity across the whole supply chain — from the drug substance itself to the delivery devices and the specialty manufacturing steps in between. Every incremental unit of oral capacity requires the kind of high-potency, solvent-intensive processing that only a handful of contract manufacturers can do at commercial scale. For a country that wants to move its pharmaceutical exports up the value chain, being a trusted node in that network is worth far more than the tonnage suggests.
The corridor, upgraded. NorthSouth HQ tracks the Portugal–Nordic relationship in both directions, and the reverse flow — Portuguese companies selling into Scandinavia — is usually told through wine, cork, textiles and footwear. Hovione is a reminder that the same corridor runs through some of the most advanced manufacturing on the continent. A Portuguese firm supplying deep-tech manufacturing capability into a Danish pharmaceutical giant is the high end of the export story: sticky, high-margin, hard to displace, and almost invisible to the consumer who eventually swallows the tablet.
Not an island. Hovione anchors a broader Portuguese pharmaceutical-chemical cluster that includes the family-owned drugmaker Bial and a growing ecosystem of specialty producers, many with European and Nordic customers. The macro backdrop favours them: European buyers, stung by pandemic-era supply shocks and wary of over-dependence on Asian API sources, are actively re-shoring and diversifying their supply chains. A high-quality, EU-based, FDA-inspected manufacturer a couple of hours’ flight from Copenhagen is exactly the kind of partner a Nordic pharmaceutical company now wants on its list.
The lesson for the corridor is that its most valuable links are often the least visible. A shipment of finished fabric or a pallet of wine bottles is easy to picture; a licensed, audited flow of high-potency pharmaceutical know-how between Loures and Denmark is not. But it is precisely those quiet, technical, deeply embedded relationships — the ones that take years to qualify and are almost never switched — that give the Portugal–Nordic axis its real depth. Hovione has been building one of them, molecule by molecule, since long before anyone had heard of Ozempic.